141 related articles for article (PubMed ID: 7601798)
1. The conduct of clinical trials and good clinical practices: the sponsor's perspective. Food and Drug Administration.
Robb EJ; Davis DD; Farrington DO
J Anim Sci; 1995 Feb; 73(2):614-9; discussion 619-21. PubMed ID: 7601798
[TBL] [Abstract][Full Text] [Related]
2. The responsibilities of investigators, monitors, and sponsors of clinical studies supporting new animal drug applications. Center for Veterinary Medicine, FDA.
Schoenemann HM; McCormack JF; Smedley KO
J Anim Sci; 1995 Feb; 73(2):606-13; discussion 612-3. PubMed ID: 7601797
[TBL] [Abstract][Full Text] [Related]
3. Data integrity-conduct of clinical investigations: university investigator perspective.
Crooker BA; Preston RL; Boyd RD
J Anim Sci; 1995 Feb; 73(2):622-7; discussion 627-8. PubMed ID: 7601799
[TBL] [Abstract][Full Text] [Related]
4. Operation of a radiopharmacy for a clinical trial.
Norenberg JP; Petry NA; Schwarz S
Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
[TBL] [Abstract][Full Text] [Related]
5. Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials.
Perez R; Archdeacon P; Roach N; Goodwin R; Jarow J; Stuccio N; Forrest A
Clin Trials; 2017 Jun; 14(3):225-233. PubMed ID: 28345368
[TBL] [Abstract][Full Text] [Related]
6. Current regulatory issues in cell and tissue therapy.
Burger SR
Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234
[TBL] [Abstract][Full Text] [Related]
7. Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example.
Black LE; Bendele AM; Bendele RA; Zack PM; Hamilton M
Toxicol Pathol; 1999; 27(1):22-6. PubMed ID: 10367668
[TBL] [Abstract][Full Text] [Related]
8. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
9. The Food and Drug Administration and pragmatic clinical trials of marketed medical products.
Anderson ML; Griffin J; Goldkind SF; Zeitler EP; Wing L; Al-Khatib SM; Sherman RE
Clin Trials; 2015 Oct; 12(5):511-9. PubMed ID: 26374684
[TBL] [Abstract][Full Text] [Related]
10. [ICH-GCP Guideline: quality assurance of clinical trials. Status and perspectives].
Englev E; Petersen KP
Ugeskr Laeger; 2003 Apr; 165(16):1659-62. PubMed ID: 12756823
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials integrity: a CRO perspective.
Beach JE
Account Res; 2001; 8(3):245-60. PubMed ID: 12481762
[TBL] [Abstract][Full Text] [Related]
12. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
13. As use of foreign drug trials grows, FDA oversight may not be keeping up.
Mitka M
JAMA; 2010 Aug; 304(8):843-4. PubMed ID: 20736460
[No Abstract] [Full Text] [Related]
14. FDA review divisions: performance levels and the impact on drug sponsors.
Milne CP; Kaitin KI
Clin Pharmacol Ther; 2012 Mar; 91(3):393-404. PubMed ID: 22336592
[TBL] [Abstract][Full Text] [Related]
15. Responsibilities of animal scientists and drug sponsors when conducting research with investigational new animal drugs.
Knight WM
J Anim Sci; 1987 Aug; 65(2):581-3. PubMed ID: 3624101
[TBL] [Abstract][Full Text] [Related]
16. Quality assurance operations: good clinical practices.
Castellion AW
Drug Inf J; 1983; 17(1):25-9. PubMed ID: 10262248
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of clinical investigations; availability of guideline--FDA. Notice.
Fed Regist; 1988 Feb; 53(31):4723-4. PubMed ID: 10285639
[TBL] [Abstract][Full Text] [Related]
18. Responsibilities of university investigators when conducting trials on investigational new animal drugs.
Parrott JC
J Anim Sci; 1987 Aug; 65(2):577-80. PubMed ID: 3624100
[TBL] [Abstract][Full Text] [Related]
19. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.
Lee JY; Garnett CE; Gobburu JV; Bhattaram VA; Brar S; Earp JC; Jadhav PR; Krudys K; Lesko LJ; Li F; Liu J; Madabushi R; Marathe A; Mehrotra N; Tornoe C; Wang Y; Zhu H
Clin Pharmacokinet; 2011 Oct; 50(10):627-35. PubMed ID: 21895036
[TBL] [Abstract][Full Text] [Related]
20. A proposed design for conducting target animal safety studies for developing new veterinary pharmaceuticals.
Carakostas MC; Colaianne JJ
Regul Toxicol Pharmacol; 1996 Feb; 23(1 Pt 1):49-54. PubMed ID: 8628920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
